Table 2 Characteristics of substances subject to patent challenges
Substances | Challenged by one manufacture | Challenged by less than 5 manufacturers | Challenged by more than 8 manufacturers | ||||
|---|---|---|---|---|---|---|---|
39 | 16 | (41 %) | 11 | (28 %) | 12 | (31 %) | |
Route | |||||||
Oral | 32 | 9 | (28 %) | 11 | (34 %) | 12 | (38 %) |
Injection | 3 | 3 | (100 %) | 0 | (0 %) | 0 | (0 %) |
Others | 4 | 4 | (100 %) | 0 | (0 %) | 0 | (0 %) |
ATC classification | |||||||
A/B/C | 18 | 4 | (22 %) | 6 | (33 %) | 8 | (44 %) |
J/L | 6 | 3 | (50 %) | 2 | (33 %) | 1 | (17 %) |
M/N | 4 | 1 | (25 %) | 1 | (25 %) | 2 | (50 %) |
Others | 11 | 8 | (73 %) | 2 | (18 %) | 1 | (9 %) |
Reimbursed | |||||||
No | 10 | 1 | (10 %) | 4 | (40 %) | 5 | (50 %) |
Yes | 29 | 15 | (52 %) | 7 | (24 %) | 7 | (24 %) |
Approved year | |||||||
1994–2005 | 8 | 4 | (50 %) | 4 | (50 %) | 0 | (0 %) |
2006–2010 | 13 | 5 | (38 %) | 3 | (23 %) | 5 | (38 %) |
2011–2016 | 18 | 7 | (39 %) | 4 | (22 %) | 7 | (39 %) |
Market size (million KRW) | |||||||
< 100,000 | 9 | 5 | (56 %) | 1 | (11 %) | 3 | (33 %) |
100,000-700,000 | 14 | 8 | (57 %) | 4 | (29 %) | 2 | (14 %) |
700,000 ≤ | 16 | 3 | (19 %) | 6 | (38 %) | 7 | (44 %) |